Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

The Treatment of Pulmonary Arterial Hypertension with the Anti-proliferative Agent Hydroxyurea

Ronan Desmond


  Sign in to add a review

Leave a Comment

Release Date: 06.06.2013

Presentation Type: Webinars

Patients with Pulmonary Arterial Hypertension share similarities with those with myeloproliferative disorders. Hydroxyurea is used routinely in this group of patients and works by decreasing hematopoietic progenitors and peripheral counts. NHLBI researcher, Dr. Ronan Desmond, discusses a hypothesis that hydroxyurea could potentially improve hemodynamic parameters in PAH. He also discusses the pre-clinical work that led to this protocol’s conception and outlines details of its upcoming clinical trial.